Correo Electrónico
DNINFOA - SIA
Bibliotecas
Convocatorias
Identidad U.N.
Publicado
Reflexiones sobre la biosíntesis de la morfina y el Parkinson idiopático
Reflections on the biosynthesis of morphine and idiopathic Parkinson's disease
Palabras clave:
Biosíntesis, morfina, Parkinson, diagnóstico (es)Biosynthesis, morphine, Parkinson's disease, diagnosis (en)
Descargas
Con base en un caso personal estudiado en forma diaria y continua se deduce que la enfermedad de Parkinson idiopática es una autointoxicación endógena por alteraciones en la biosíntesis de la morfina, y se propone la determinación de los niveles de ésta en la sangre tanto en los parkinsonianos antes de cualquier tratamiento y, con el fin de establecer su diagnóstico preclínico, en los depresivos que constituyen el grupo mas afectado por la enfermedad de Parkinson.
Based on a day-by-day, in-depth study of a clinical case, it was deduced that Parkinson's disease results in autointoxication, due to damage to morphine biosynthesis. Blood morphine levels should be studied in patients suffering from Parkinson's disease before treatment as well as in depressive patients (being the group most affected by Parkinson´s disease) to achieve early preclinical diagnosis.
Referencias
Huxtable RJ, Schwarz SK. The isolation of morphine - first principles in science and ethics. Mol Interv 2001;1:189-91.
Mavrojannis M. L´action cataleptique de la morphine chez les rats. Contribution à la théorie toxique de la catalepsie. C R Soc Biol 1903;55:1092-4.
Davis VE, Walker MJ. Alcohol, amines, and alkaloids: a possible biochemical basis for alcohol addiction. Science 1970;167:1005-7.
Gintzler AR, Levy A, Spector S. Antibodies as a means of isolating and characterizing biologically active substances: Presence of a non-peptide, morphine-like compound in the central nervous system. Proc Natl Acad Sci USA 1976; 73:2132-6.
Weitz CJ, Lowney LI, Faull KF, Feistner G. Morphine and codeine from mammalian brain. Proc Natl Acad Sci USA 1986; 83:9784-8.
Shorr J, Foley K, Spector S. Presence of a non-peptide morphine-like compound in human cerebrospinal fluid. Life Sci 1978;23:2057-62.
Poeaknapo C. Mammalian morphine: de novo formation of morphine in human cells. Med Sci Monit 2005; 11:MS6-17.
Hazum E, Sabatka JJ, Chang KJ, Findlay JWA, Cuatrecasas P. Morphine in cow and human milk: could dietary morphine constitute a ligand for specific morphine (?) receptors? Science 1981; 213:1010-2.
Kream RM, Stefano GB. De novo biosynthesis of morphine in animal cells-based model. Med Sci Monitor 2006; 12(10): 207-19.
Matsubara K, Fukushima S, Akane H, Kobayashi S, Shiono H. Increase urinary morphine, codeine and tetrahydropapaveroline in parkinsonian patient undergoing L-3,4-dihydroxyphenylalanine therapy: a possible biosynthetic pathway of morphine from L-3,4-dihydroxyphenylalanine in humans. J Pharmacol Exp Ther 1992; 260:974-8.
Parkinson J. An essay on the shaking palsy. Sherwood, Neely, Jones. London, 1817. Reprinted in J Neuropsychiatry Clin Neurosci 2002;14:223-36.
Goetz CG. Charcot on Parkinson´s disease. Mov Disord 1986;1:27-32.
Uribe MG, Rueda MG. Parkinsonismo de etiología tóxica. En: Neurotoxicología, Uribe Granja MG. Asociación Colombiana de Toxicología (Ed.), Bogotá: E-Libris; 2000.
Lang AE. Neuroprotection in Parkinson's disease: and now for something completely different? Lancet Neurology;2006;5:990-1.
Olanow CW, Schapira AHV, LeWitt PA, Kieburtz K, Sauer D, Olivieri G, Pohlmann H, Hubble J. TCH346 as a neuroprotective drug in Parkinkinson's disease: a double blind, randomised, controlled trial. Lancet Neurol 2006;5:1013-20.
Waldmeier P, Bozyczko-Coyne D, Williams M, Vaught JL. Recent clinical failures in Parkinson´s disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases. Biochem Pharmacol 2006;72:1197-206.
Unterharnscheidt F, A neurologist's reflections on boxing. V. Conclude remarks. Rev Neurol 1995 Sep-Oct;23(123):1027-32.
Hoehn M, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
Williams AC, Ramsden DB. Autotoxicity, methylation and a road to the prevention of Parkinson's disease. J Clin Neurosci 2005 Jan;12(1):6-11.
Haavik J, Tosta K. Tyrosine hydroxylase and Parkinson's disease. Molecular Neurobiology 1998;16: 285-309.
Pearce LA, Waterbury LD. L-methionine: a possible levodopa antagonist. Neurology 1974;24:840-1.
Di Rocco A, Rogers JD, Brown R, Werner P, Bottiglieri T. S-Adenosyl-Methionine improves depression in patients with Parkinson's disease in an open-label clinical trial. Mov Disord 2000 Nov;15(6):1225-9.
Lauterbach EC. The neuropsychiatry of Parkinson's disease and related disorders. Psychiatr Clin North Am 2004;27:801-25.
Mayeux R, Stern Y, Williams JB, Cote L, Frantz A, Dyrenfurth I. Clinical and biochemical features of depression in Parkinson's disease. Am J Psychiatry 1986; 143:756-9.
Kurup RK, Kurup PA. Hypothalamic digoxin-mediated model for Parkinson's disease. Int J Neurosci 2003 Apr;113(4):515-36.
Cadet P, Zhu W, Mantione KJ, Rymer M, Dardik I, Reisman S, Hagberg S, Stefano GB. Cyclic exercise induces anti-inflammatory signal molecule increases in the plasma of Parkinson´s patients. Int J Mol Med 2003 Oct;12(4):485-92.
Matsubara K, Gonda T, Sawada H, Uezono T, Kobayashi Y, Kawamura T, Ohtaki K, Kimura K, Akaike A. Endogenously occurring beta-carbolines induces parkinsonism in non-primate animals: a possible causative protoxin in idiopathic Parkinson's disease. J Neurochem 1998;70:727-35.
Matsubara K, Aoyama K, Suno W, Awaya T. N-methylation underlying Parkinson´s disease. Neurotoxicol Teratol 2002 Sep-Oct;24(5):593-8.
Hofmann U, Seefried S, Schweizer E, Ebner T, Mikus G, Eichelbaum M. Highly sensitive gas chromatographic-tandem mass spectrometric method for the determination of morphine and codeine in serum and urine in the femtomolar range. J Chromatogr B Biomed Sci Appl 1999 Apr 30;727(1-2):81-8.
Horak P, Haberman F, Spector S. Endogenous morphine and codeine in mice-effect of muramyl peptide. Life Sci 1993;52:PL255-63.
Forman MS, Lee VM, Trojanowski JQ. Nosology of Parkinson´s disease: looking for the way out of a quackmire. Neuron 2005;47:479-82.
Fung HC, Scholz S, Matarin M, Simón-Sánchez J, Hernández D, Britton A, Gibbs JR, Langefeld C, Stiegert MI, Schymick J, Okun MS, Mandel RJ, Fernández HH, Foote KD, Rodríguez RL, Peckham E, Wavrant de Vrieze F, Gwinn-Hardy K, Hardy JA, Singleton A. Genome-wide genotyping in Parkinson's disease and neurologically normal controls; first stage analysis and public release of data. Lancet Neurology 2006;5:911-6.
Poeaknapo C, Schmidt J, Brandsch M, Dräger B, Zenk MH. Endogenous formation of morphine in human cells. Proc Natl Acad Sci (USA) 2004;191:14091-6.
Olsen P, Rasmussen M, Zhu W, Toennesen E, Stefano GB. Human gliomas contain morphine. Med Sci Monit 2005; 11:MS18-21.
Cardinale GJ, Donnerer J, Finck AD, Kantrowitz JD, Oka K, Spector S. Morphine and codeine are endogenous components of human cerebrospinal fluid. Life Sci 1987; 40:301-6.
Cómo citar
APA
ACM
ACS
ABNT
Chicago
Harvard
IEEE
MLA
Turabian
Vancouver
Descargar cita
Visitas a la página del resumen del artículo
Descargas
Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Esta revista provee acceso libre inmediato a su contenido bajo el principio de que hacer disponible gratuitamente investigación al publico apoya a un mayor intercambio de conocimiento global.
Todos los contenidos de esta revista, excepto dónde está identificado, están publicados bajo una Licencia Creative Commons Atribución 4.0.
